Date: 2017-09-18
Type of
information: Clinical trial authorisation
phase: 2
Announcement: clinical trial authorisation
Company: Allergy Therapeutics (UK)
Product: PQ Grass
Action
mechanism:
- immunotherapy product. PQ Grass is an ultra-short course, aluminium free subcutaneously injected product with the potential to cure grass pollen-induced allergic rhinitis.
Disease: grass pollen-induced allergic rhinitis
Therapeutic
area: Allergic diseases
Country: Austria, Germany, Poland, Sweden
Trial
details:
Latest
news:
- • On September 18, 2017, Allergy Therapeutics announced that the fully-funded Phase II clinical trial investigating the dosing of PQ Grass has received clinical trial application (CTA) approval. The company expects the Phase II trial to begin imminently. The trial will take place in Europe in Germany, Poland and Austria and will involve approximately 440 patients. The results of the trial are expected in H2 2018. The trial is part of a continuing clinical trial programme aimed at developing the PQ Grass platform worldwide. Following completion of this trial, meetings with the regulatory authorities in the US and Germany will be necessary before it progresses to a Phase III trial. The US market, which is anticipated to be the main market for this product if successful, is estimated by Allergy Therapeutics to be worth $2bn with potential peak sales of $300m per annum.
Is
general: Yes
